Proving the economic advantages of decentralized trials
Download “Making The Economic Case For Decentralized Clinical Trials”
Although the popularity of the decentralized clinical trial (DCT) model is on the rise and its benefits in improving patient-centricity and streamlining major trial tasks are well-known, sponsors can still be wary, wondering if DCTs can really elevate their bottom line.
Citeline, in partnership with ICON, explores the results of a recent Tufts Center for the Study of Drug Development study quantifying the financial value of DCTs based on three key performance indicators (KPIs). Access this revealing analysis of the true economic viability of the decentralized clinical trial model.
White Paper from 
If your Download does not start Automatically, Click Download Whitepaper